The French Life Sciences Trend Analysis 2015
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
The French Life Sciences Trend Analysis 2015
About Us
The following statistical information has been obtained from Biotechgate. Biotechgate is a global, comprehensive, Life Sciences database encompassing the Biotechnology, Pharmaceutical and Medical Device industries. www.biotechgate.com
The French Life Sciences Database is a part of the global Biotechgate and is brought to you in partnership with Alsace BioValley. www.frenchbiotech.com
Biotechgate is owned and operated by Venture Valuation AG, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the Life Sciences (Biotech, Pharma, Medtech), ICT, high-tech, Nanotech, Cleantech and Renewable energy. www.venturevaluation.com
Overview of the French Life Science Industry
2015 Statistics
Total Biotech Companies 721
Medtech companies 162
Pharma companies 95
Investor companies 22
Public / Non-Profit Organizations / Medical Facilities 454
Other life science related companies 499
Percentage of Publicly Owned Companies 4%
Life Sciences Venture Financing 2013 / 2014 USD 209.2m / USD 143.4m
Number of Technologies 273
Licensing Opportunities 336
Overview of the French Biotechnology Industry
2015 Statistics
Total Biotech Companies 721
Biotech - Therapeutics 139
Biotech – R&D Services 387
Biotech - Other 195
Percentage of SME's 87%
Percentage of Publicly Owned Companies 5.7%
Biotech Venture financing 2013 / 2014 USD 138.43m / USD 85.24m
Licensing Opportunities 221
Number of Employees
1-1020%
11-5036%51-200
21%
Greater than 200
22%
Number of Employees - Life Sciences
1-1027%
11-5043%
51-20017%
Greater than 20013%
Number of Employees - Biotech
Company Ownership
Life Science Companies by Ownership Status
Life Science Companies by Ownership Status
Life Science companies include Biotech, Medtech and Pharmaceutical companies.
Private / inde-
pendent71.1%
Public6.6%
Sub-sidiary22.3%
Life Science Companies by Ownership Status
Private / independent 74%
Public5.7%
Subsidiary19.3%
Biotechnology Companies by Ownership Status
Company Foundation Timeline
20052006
20072008
20092010
20112012
20132014
20150
5
10
15
20
25
30
35
Number of Biotech Companies Founded by Year
Biotechnology - other Biotechnology - Therapeutics and Diagnostics Biotechnology / R&D Services
Key Activities of Biotechnology Companies
AgroBio3% Bioinformatics and Bioelectronics
3%
Contract Research and Manufacturing16%
Cosmetics4%
Diagnostics and Analytical Services17%
Drug Delivery2%Environment
3%Food and Nutraceuticals
6%Genomics and Proteomics
5%
Industrial Biotechnology2%
Other Services and Suppliers25%
Therapeutics11%
Veterinary3%
Key Biotech Activity
Biotech Products - Breakdown by Indication
Neoplasms / cancer / oncologyother
Infectious and parasitic diseasesDiseases of the nervous system
Endocrine, nutritional and metabolic diseasesDiseases of the eye
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classifiedDigestive system
Musculoskeletal system and connective tissueCardiovascular
Skin and subcutaneous tissueDiseases of the blood and blood-forming organs; immune disorders
Genitourinary systemRespiratory
Injury, poisoning and certain other consequences of external causesCongenital malformations, deformations and chromosomal abnormalities
Mental and behavioural disordersDiseases of the ear
Pregnancy, childbirth and the puerperiumExternal causes of morbidity and mortality
Conditions originating in the perinatal period
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
Biotech Products by Indication
Products in the Pipeline as of 07.10.2015
Phase III
Phase II
Phase I
Preclinical
0 20 40 60 80 100 120
20
72
42
117
Number of Biotech Products in Development
Biotechnology Financing in France – 5 year report
H2 of 2015 includes data until 07.10.2015
2010 H1
2010 H2
2011 H1
2011 H2
2012 H1
2012 H2
2013 H1
2013 H2
2014 H1
2014 H2
2015 H1
2015 H2
2010 H1
2010 H2
2011 H1
2011 H2
2012 H1
2012 H2
2013 H1
2013 H2
2014 H1
2014 H2
2015 H1
2015 H2
Financ-ing Value
72.7144342
38.6996675
21.9147427
5
42.598602
30.0267467
96.6005055
103.29877346798
8
35.1333906
55.059179097738
8
30.176881522038
6
29.649060614480
3
42.168080185042
4
Number of Rounds
7 7 7 3 9 10 9 6 12 6 6 3
10.0
30.0
50.0
70.0
90.0
110.0
0.5
2.5
4.5
6.5
8.5
10.5
12.5
Venture Financing of Biotech Companies
Financing Value
Number of Rounds
Finan
cing V
alue
(Milli
on U
SD)
Num
ber o
f Rou
nds
Major Biotech Financing Rounds (2015)
Company Sector USD M
GenSight Biologics Biotech – Therapeutics & Diagnostics 36.0
Genkyotex Innovation SAS Biotech – Therapeutics & Diagnostics 21.7
InnaVirVax SA Biotech – Therapeutics & Diagnostics 3.9
About Biotechgate
Biotechgate contains over 35’000 high quality company profiles which include company descriptions, contact information, product pipeline information, financing rounds and management details. Profiles are regularly updated by the companies themselves, as well as by an experienced database team, to ensure the accuracy and relevance of the data.
To register for a trial or to learn more about the different subscription options, please visit www.biotechgate.com
Terms of Use
The “French Life Sciences Trend Analysis” is based on data entered in the Biotechgate Database available at www.biotechgate.com. The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.
The use of the figures and graphs provided in this report is free of charge for any presentations as long as www.biotechgate.com is clearly cited as the source. For all other uses please contact us for terms and conditions.
Biotechgatec/o Venture Valuation VV AGKasernenstrasse 118004 ZurichSwitzerland
+41 (43) 321 86 60 www.venturevaluation.com
Related Documents
